PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “Wnt3a alternative peptide (β-catenin pathway agonist)” which has equivalent function to recombinant Wnt3a as well as GSK-3β inhibitors, such as CHIR99021(CHIR)). This product will be available in the middle of November 2023. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600M Japanese yen ($4M USD) through Third-Party Allotment
Cumulative Funds Raised Amount to Approximately 1.7 billion yen (Approximately $11.3 million USD)
KOBE, Japan — VCCT Inc. (President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD). The allotment involved new shares to Sysmex Corporation (President: Kaoru Asano), DAI-DAN CO., LTD. (Representative Director, President: Ichiro Fujisawa), and YASKAWA Electric Corporation (Representative Director, President: Masahiro Ogawa). VCCT will continue to accelerate the development of retinal regenerative medicine together with these partners. [Read more…]
Ajinomoto Co. to Acquire Gene Therapy CDMO Forge Biologics for an Astounding $620 Million
- Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services
- Positions Forge Biologics for accelerated long-term growth supporting gene and cell therapy clients worldwide
Atsena Therapeutics Receives FDA RMAT Designation for ATSN-101 Gene Therapy
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1
ATSN-101 has demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment in ongoing Phase I/II clinical trial
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
TORONTO and HAIFA, Israel — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its ExoPTEN therapy, recognizing the potential of this groundbreaking regenerative therapy for acute spinal cord injury, a condition where effective treatments are limited. [Read more…]
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 145
- Next Page »